



FOR RETINA SPECIALISTS

Access SUSVIMO With Confidence (2026)



s u s v i m o®
ranibizumab injection 100 mg/mL
For Ocular Implant

Access and Reimbursement Guide

The first and only continuous delivery treatment for nAMD, DME and DR

Indications

SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR) who have previously responded to at least 2 intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor.

Important Safety Information

WARNING: ENDOPHTHALMITIS

The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab.

- 2 Ordering SUSVIMO
- 4 Billing and Coding
- 6 Financial Assistance
- 10 Additional Resources

Please see additional Important Safety Information in the full SUSVIMO Prescribing Information, including **BOXED WARNING**.

Genentech
A Member of the Roche Group

SUSVIMO Vial Ordering Guide for Refill Procedures (2026)

BOTH COMPONENTS must be ordered for the SUSVIMO refill procedure:

SUSVIMO 100 mg/mL Vial



Components	SUSVIMO (ranibizumab injection) 100 mg/mL Vial
Product numbers	10-digit NDC: 50242-078-12
	11-digit NDC: 50242-0078-12
WAC	\$8,000.00*
Dimensions	2.72 in × 4.52 in × 1.3 in
Storage	Store between 2 °C to 8 °C (36 °F to 46 °F)

SUSVIMO Refill Needle



Components	Refill needle
Product numbers	GTIN: 00810042590045
	Truncated GTIN: 81004259004
WAC	\$0.00
Dimensions	2.19 in × 0.63 in × 3.75 in
Storage	Store at ambient temperature (15 °C to 25 °C [59 °F to 77 °F]) Cannot be stored under refrigerated conditions

Each component may arrive in 2 separate packages or together in a cold chain shipper, depending on your distributor. See above for storage information following arrival.

GTIN=Global Trade Identification Number; NDC=National Drug Code; WAC=wholesale acquisition cost.

*Additional discounts may be available.

Please see additional Important Safety Information in the full SUSVIMO Prescribing Information, including **BOXED WARNING**.



Distributors for Required Materials for SUSVIMO Refill Procedures (2026)

Authorized specialty distributors for SUSVIMO

SUSVIMO can be procured through a select list of specialty distributors.

	Phone	Web/Email	Ordering numbers*	
			SUSVIMO 100 mg/mL Vial	SUSVIMO Refill Needle
Besse Medical[†]	(800) 543-2111	besse.com	10263102	10290959
		csorders@besse.com		
BioCareSD	(800) 304-3064	biocare-us.com	1002100	1002102
Cardinal Health Puerto Rico	(787) 625-4200	orderexpress.cardinalhealth.com	5780473	5933999
		cuserv@cardinalhealth.com		
Cardinal Health Specialty	(877) 488-3572	specialtyonline.cardinalhealth.com	5756382	5933833
		GMB-SPD-MFGSERVICESSP@cardinalhealth.com		
CuraScript SD	(877) 599-7748	curascriptsd.com	10003436	20000086
		Customer.Service@curascript.com		
DMS Pharmaceuticals	(847) 518-1100	customerservice@dms.pharma.com	3995	6901
Henry Schein	(800) 772-4346	henryschein.com	1499996	1499995
		custserv@henryschein.com		
McKesson Medical-Surgical	(855) 571-2100	mms.mckesson.com	1284268	1284267
		customerservice@mckesson.com		
McKesson Plasma and Biologics[‡]	(877) 625-2566	connect.mckesson.com	2374700	2645448
		MPB0orders@McKesson.com		
McKesson Specialty Health[‡]	(855) 477-9800	MSH.CustomerCare-MSPL@McKesson.com	5011632	5503481
Metro Medical	(800) 768-2002	metromedicalorder.com	800204	800207
		customersvc@cardinalhealth.com		

Specialty distributor list does not include all distributors for federal accounts.

List as of May 8, 2026. Please visit Genentech-Access.com/SUSVIMO to view the latest list.

Have a question about how to obtain SUSVIMO?

 Visit SUSVIMO.com/support

 Call the Genentech Ophthalmology Support Line at **(833) EYE-GENE/(833) 393-4363** from 9 a.m.-8 p.m. ET, Monday-Friday. Press 2 to order additional SUSVIMO ancillary tools (e.g., Refill Needles)

 Get support from a **Genentech Ophthalmology Representative**

*Confirm with your authorized specialty distributor the appropriate code for each component.

[†]Also accepts Puerto Rico orders.

[‡]For Veterans Affairs customers, the ordering number is the NDC.

Genentech does not influence or advocate the use of any one specialty distributor or specialty pharmacy. We make no representation or guarantee of service or coverage of any item.

Please see additional Important Safety Information in the full SUSVIMO Prescribing Information, including **BOXED WARNING**.

 **susvimo**[®]
ranibizumab injection 100 mg/mL
For Ocular Implant

Sample Drug and Administration Codes for Refill Procedures (2026)

This coding information may assist you as you submit claims for reimbursement for SUSVIMO.

Sample drug and administration codes for refill procedure

Biller	Code		Description
Retina specialist office	NDC	10-digit 50242-078-12	SUSVIMO (ranibizumab injection) 100 mg/mL vial
		11-digit 50242-0078-12	
	HCPCS	J2779	Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg
	HCPCS modifier*	JZ	Zero drug amount discarded/not administered to any patient
	Professional services: CPT	67028	Intravitreal injection of a pharmacologic agent (separate procedure)
	CPT modifier	-LT	Left eye modifier
		-RT	Right eye modifier



SUSVIMO billing direction

Bill 100 units with J2779 and the JZ modifier for the 10-mg single-dose vial of SUSVIMO*



The latest sample codes, including ICD-10-CM diagnosis codes for nAMD, DME and DR, are available at [SUSVIMO.com/samplecodes](https://www.susvimo.com/samplecodes).

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; DME=diabetic macular edema; DR=diabetic retinopathy; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; nAMD=neovascular (wet) age-related macular degeneration; NDC=National Drug Code; RT=right.

*SUSVIMO meets criteria for an exemption for wastage based on requiring filtration prior to administration for both the implant and refill procedures. The JZ modifier is required on claims for all single-dose containers or single-use drugs when no drug is discarded/administered to any patient as of July 1, 2023. For more information on the JZ modifier, visit CMS.gov.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Please see additional Important Safety Information in the full SUSVIMO Prescribing Information, including **BOXED WARNING**.



SUSVIMO Refill Sample Claim Form: CMS-1500

Typically used for refill procedures in retina specialist office settings

The CMS-1500 claim form is used to bill for services provided in the retina specialist office setting. The CMS-1500 claim form is shown here as an example. Check with individual payers for specific documentation requirements.

21 Insert appropriate ICD-10-CM diagnosis code(s).

24A Report NDC information in the shaded area in the following order: N4 qualifier, 11-digit NDC followed by 1 space, unit of measurement qualifier and metric quantity.

- Example N4 qualifier for refill: **N450242007812 ML0.1**
- Payer requirements for placement of the NDC and N4 qualifier may differ. Please confirm specific documentation requirements with individual payers

24B Enter the appropriate place of service: **11 for retina specialist office.**

24D Document use of drug with the appropriate HCPCS code on 1 line and the appropriate CPT administration code, **67028**, on a separate line. Specify if treatment was administered in the left (LT) or right (RT) eye.

- **Bill 100 units with J2779 and the JZ modifier for the 10-mg single-dose vial of SUSVIMO***

HEALTH INSURANCE CLAIM FORM
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 0212

21 ICD-10-CM diagnosis code

24A NDC and unit information

24B Place of Service

24D HCPCS and CPT codes

NUCC Instruction Manual available at: www.nucc.org PLEASE PRINT OR TYPE APPROVED OMB-0938-1197 FORM 1500 (02-12)

24G Include the number of units used (**100**) for each line item.

*SUSVIMO meets criteria for an exemption for wastage based on requiring filtration prior to administration for both the implant and refill procedures. The JZ modifier is required on claims for all single-dose containers or single-use drugs when no drug is discarded/administered to any patient as of July 1, 2023. For more information on the JZ modifier, visit CMS.gov.

Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Completion of other fields may be required. Check with individual payers for more information.

Please see additional Important Safety Information in the full SUSVIMO Prescribing Information, including **BOXED WARNING**.

susvimo®
ranibizumab injection 100 mg/mL
For Ocular Implant

• Drug and Administration Co-pay Assistance From the Genentech Ophthalmology Co-pay Program

Eligible commercially insured patients pay as little as:

\$0

per drug co-pay, up to
\$15,000 per calendar year

\$0

per surgical procedure and refill
co-pays, up to \$1,000 per calendar year

For more information or to get started:



 **Scan or click** this QR code to visit EyeOnCopoly.com

 **Call** (855) 218-5307 from 9 a.m.-8 p.m. ET, Monday-Friday

 **Enroll** patients directly using the Prescriber Service Form and Patient Consent Form

The Product and Administration Co-pay Programs ("Programs") are valid ONLY for patients with commercial (private or non-governmental) insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medicine. The Programs are not available to patients whose prescriptions are reimbursed under any federal, state, or government-funded insurance programs (included but not limited to Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs Programs) or where prohibited by law or by the patient's health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state or government-funded healthcare programs, the patient will no longer be eligible for the Programs.

Under the Programs, the patient may be required to pay a co-pay for drug costs and a co-pay for administration costs. The final amount owed by a patient may be as little as \$0 for the Genentech medicine or administration of the Genentech medicine (see Program specific details available at the Program website). The total patient out-of-pocket cost is dependent on the patient's health insurance plan. The Programs assist with the cost of the Genentech medicine and the administration of the Genentech medicine only. It does not assist with the cost of other administrations, medicines, procedures or office visit fees. After reaching the maximum Programs' benefit amounts, the patient will be responsible for all remaining out-of-pocket expenses. The amount of the Programs' benefits cannot exceed the patient's out-of-pocket expenses for the cost of the Genentech medicine or administration fees for the Genentech medicine.

Please see additional Important Safety Information in the full
SUSVIMO Prescribing Information, including **BOXED WARNING**.

 **susvimo**[®]
ranibizumab injection 100 mg/mL
For Ocular Implant

Independent Co-pay Assistance Foundations



An independent co-pay assistance foundation is a charitable organization providing financial assistance to patients with specific disease states, regardless of treatment. Patients who are commercially or publicly insured, including those covered by Medicare and Medicaid, can contact the foundations directly to request assistance.

For more information or to get started:



Scan or click this QR code for a list of independent co-pay assistance foundations



Call (866) 724-9394 from 9 a.m.-8 p.m. ET, Monday-Friday

Independent co-pay assistance foundations have their own rules for eligibility. Genentech has no involvement or influence in independent foundation decision-making or eligibility criteria and does not know if a foundation will be able to help your patient. We can only refer your patient to a foundation that supports their disease state. Genentech does not endorse or show preference for any particular foundation. The foundations to which we refer your patient may not be the only ones that might be able to help.

All participants are responsible for reporting the receipt of all Programs' benefits as required by any insurer or by law. The Programs are only valid in the United States and U.S. Territories and are void where prohibited by law. The Drug Co-pay Program shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The Administration Co-pay Program is not valid for patients who reside or receive treatment in a restricted state (e.g. Massachusetts or Rhode Island). No party may seek reimbursement for all or any part of the benefit received through the Programs. The value of the Programs is intended exclusively for the benefit of the patient. The funds made available through the Programs may only be used to reduce the out-of-pocket costs for the patient enrolled in the Programs. The Programs are not intended for the benefit of third parties, including without limitation third party payers, pharmacy benefit managers, or their agents. If Genentech determines that a third party has implemented programs that adjust patient cost-sharing obligations based on the availability of support under the Programs and/or excludes the assistance provided under the Programs from counting towards the patient's deductible or out-of-pocket cost limitations, Genentech may impose a per fill cap on the cost-sharing assistance available under the Programs. Submission of true and accurate information is a requirement for eligibility and Genentech reserves the right to disqualify patients who do not comply with Genentech Program Terms and Conditions. Genentech reserves the right to rescind, revoke or amend the Programs without notice at any time.

Additional terms and conditions apply. Please visit the co-pay Program website for the full list of Terms and Conditions.

Please see additional Important Safety Information in the full SUSVIMO Prescribing Information, including **BOXED WARNING**.

 **susvimo**[®]
ranibizumab injection 100 mg/mL
For Ocular Implant

Free SUSVIMO for Eligible Patients From the Genentech Patient Foundation

Genentech Patient Foundation

Is My Patient Eligible?

Genentech Patient Foundation eligibility depends on your patients' health insurance and financial situation. They may qualify if they are in 1 of the 3 groups below.



1. "I have **no insurance**."

For a household of 1 to 4 people, total yearly income is under \$150,000.

- For households with more than 4 people, add \$25,000 to the yearly income limit for each additional person



2. "I **have insurance**, but it doesn't cover my Genentech medicine."



3. "I **have insurance** that covers my Genentech medicine, but the out-of-pocket maximum set by my health insurance plan is more than 7.5% of my yearly income."

Household size	Yearly income
1 person	Under \$75,000
2 people	Under \$100,000
3 people	Under \$125,000
4 people	Under \$150,000

For households with more than 4 people, add \$25,000 to the yearly income limit for each additional person.

Not sure if your patient is eligible?

- Call **(888) 941-3331** to speak with a live Foundation Specialist
 - We offer support in many different languages
- Visit **GenentechPatientFoundation.com** for more information

Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted.

Genentech
A Member of the Roche Group

Patient
Foundation

• Indications and Important Safety Information

Indications

SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR) who have previously responded to at least 2 intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor.

Important Safety Information

WARNING: ENDOPHTHALMITIS

The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab.

Contraindications

- Ocular or periocular infections
- Active intraocular inflammation
- Hypersensitivity

Warnings and Precautions

- The SUSVIMO implant and/or implant-related procedures have been associated with endophthalmitis, rhegmatogenous retinal detachment, implant dislocation, septum dislodgement, vitreous hemorrhage, conjunctival erosion, conjunctival retraction, and conjunctival blebs. Patients should be instructed to report any signs or symptoms that could be associated with these events without delay. Additional surgical and/or medical management may be required
- Vitreous hemorrhage: Temporarily discontinue antithrombotic medication prior to the implant insertion procedure to reduce the risk of vitreous hemorrhage. Vitrectomy may be needed
- Postoperative decrease in visual acuity: A decrease in visual acuity usually occurs over the first 2 postoperative months

Adverse Reactions

The most common adverse reactions ($\geq 10\%$) were conjunctival hemorrhage, conjunctival hyperemia, iritis, eye pain, conjunctival disorder, cataract, and vitreous hemorrhage.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch.
You may also report side effects to Genentech at (888) 835-2555.

Links to Helpful Resources and Information



Genentech Ophthalmology Patient Support Services Enrollment: **Prescriber Service Form and Patient Consent Form**



My Patient Solutions® for Health Care Practices to work with Genentech Ophthalmology Access Solutions online



SUSVIMO.com/support for resources for your patients and practice, including considerations for composing an appeal letter and a sample appeal letter



The Genentech Ophthalmology Co-pay Program for more information or to enroll patients directly



Referrals to **independent co-pay assistance foundations** for patient financial support



SUSVIMO.com/samplecodes for the latest sample codes, including ICD-10-CM diagnosis codes for nAMD, DME and DR

Need assistance?

Contact your local Field Reimbursement Manager



susvimo®

ranibizumab injection 100 mg/mL
For Ocular Implant

The Access *You* Need, For the Dosing *They* Need

- Visit **SUSVIMO.com/support**
- Call our Specialists at **(833) EYE-GENE/(833) 393-4363**
- Get support from a **Field Reimbursement Manager (FRM)**
- Manage your patients online with
My Patient Solutions® for Health Care Practices

Reference: SUSVIMO. Package insert. South San Francisco, CA: Genentech, Inc. 2025.

Please see additional Important Safety Information in the full
SUSVIMO Prescribing Information, including **BOXED WARNING**.

SUSVIMO® and My Patient Solutions® are registered trademarks
and the SUSVIMO logo is a trademark of Genentech, Inc.

©2025 Genentech USA, Inc. So. San Francisco, CA
All rights reserved. M-US-00029961(v1.0) 11/25

Genentech
A Member of the Roche Group

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use SUSVIMO safely and effectively. See full prescribing information for SUSVIMO.

SUSVIMO® (ranibizumab injection) for intravitreal use via SUSVIMO ocular implant
Initial U.S. Approval: 2006

WARNING: ENDOPHTHALMITIS

See full prescribing information for complete boxed warning.

The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab.

RECENT MAJOR CHANGES

Indications and Usage, Diabetic Macular Edema (DME) (1.2)	2/2025
Indications and Usage, Diabetic Retinopathy (DR) (1.3)	5/2025
Dosage and Administration (2.3, 2.9, 2.10)	5/2025
Warnings and Precautions (5.1, 5.5, 5.6, 5.7, 5.8)	5/2025
Warnings and Precautions (5.9)	9/2025

INDICATIONS AND USAGE

SUSVIMO (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with:

- Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor (1.1).
- Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a VEGF inhibitor (1.2).
- Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a VEGF inhibitor (1.3).

DOSAGE AND ADMINISTRATION

- For intravitreal use via SUSVIMO ocular implant. (2.1)
- Neovascular (wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
The recommended dose of SUSVIMO (ranibizumab injection) is 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the SUSVIMO implant with refills every 24 weeks (approximately 6 months). (2.2)
- Diabetic Retinopathy (DR)

The recommended dose of SUSVIMO (ranibizumab injection) is 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the SUSVIMO implant with refills every 36 weeks (approximately 9 months). (2.3)

- Supplemental treatment with 0.5 mg intravitreal ranibizumab injection may be administered in the affected eye if clinically necessary. (2.4)
- Perform the initial implantation, refill-exchange, and implant removal (if necessary) procedures under strict aseptic conditions. (2.5, 2.6, 2.7, 2.8)

DOSAGE FORMS AND STRENGTHS

Injection: 100 mg/mL solution in a single-dose vial (3)

CONTRAINDICATIONS

- Ocular or periocular infections (4.1)
- Active intraocular inflammation (4.2)
- Hypersensitivity (4.3)

WARNINGS AND PRECAUTIONS

- The SUSVIMO implant and/or implant-related procedures have been associated with endophthalmitis, rhegmatogenous retinal detachment, implant dislocation, septum dislodgement, vitreous hemorrhage, conjunctival retraction, conjunctival erosion, and conjunctival bleb. Patients should be instructed to report signs or symptoms that could be associated with these events without delay. Additional surgical and/or medical management may be required. (5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7)
- Vitreous Hemorrhage: Temporarily discontinue antithrombotic medication prior to the implant insertion procedure to reduce the risk of vitreous hemorrhage. Vitrectomy may be needed. (5.5)
- Postoperative Decrease in Visual Acuity: A decrease in visual acuity usually occurs over the first two postoperative months. (5.8)

ADVERSE REACTIONS

The most common adverse reactions ($\geq 10\%$) were conjunctival hemorrhage, conjunctival hyperemia, iritis, eye pain, conjunctival disorder, cataract and vitreous hemorrhage. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 9/2025

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: ENDOPHTHALMITIS

1 INDICATIONS AND USAGE

- 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- 1.2 Diabetic Macular Edema (DME)
- 1.3 Diabetic Retinopathy (DR)

2 DOSAGE AND ADMINISTRATION

- 2.1 General Information
- 2.2 Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
- 2.3 Diabetic Retinopathy (DR)
- 2.4 Supplemental Treatment with Intravitreal Ranibizumab Injection
- 2.5 Ocular Implant Initial Fill
- 2.6 Ocular Implant Insertion
- 2.7 Ocular Implant Removal
- 2.8 Ocular Implant Refill-Exchange Procedure
- 2.9 Delayed or Missed Doses
- 2.10 Dosage (Refill-Exchange) Modifications for Adverse Reactions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

- 4.1 Ocular or Periocular Infections
- 4.2 Active Intraocular Inflammation
- 4.3 Hypersensitivity

5 WARNINGS AND PRECAUTIONS

- 5.1 Endophthalmitis
- 5.2 Rhegmatogenous Retinal Detachment
- 5.3 Implant Dislocation
- 5.4 Septum Dislodgement

- 5.5 Vitreous Hemorrhage
- 5.6 Conjunctival Erosion or Retraction
- 5.7 Conjunctival Bleb
- 5.8 Postoperative Decrease in Visual Acuity
- 5.9 Postoperative Intraocular Inflammation
- 5.10 Air Bubbles Causing Improper Filling of the Implant
- 5.11 Deflection or Movement of the Implant

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- #### 8 USE IN SPECIFIC POPULATIONS
- 8.1 Pregnancy
 - 8.2 Lactation
 - 8.3 Females and Males of Reproductive Potential
 - 8.4 Pediatric Use
 - 8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics
- 12.6 Immunogenicity

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- 14.2 Diabetic Macular Edema (DME)
- 14.3 Diabetic Retinopathy (DR)

16 HOW SUPPLIED/STORAGE AND HANDLING

- 16.1 How Supplied
- 16.2 Storage

17 PATIENT COUNSELING INFORMATION

FULL PRESCRIBING INFORMATION

WARNING: ENDOPHTHALMITIS

The SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. Many of these events were associated with conjunctival retractions or erosions. Appropriate conjunctiva management and early detection with surgical repair of conjunctival retractions or erosions may reduce the risk of endophthalmitis. *[see Contraindications (4.1), Warnings and Precautions (5.1)].*

1 INDICATIONS AND USAGE

1.1 Neovascular (wet) Age-related Macular Degeneration (AMD)

SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication.

1.2 Diabetic Macular Edema (DME)

SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication.

1.3 Diabetic Retinopathy (DR)

SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication.

2 DOSAGE AND ADMINISTRATION

2.1 General Information

For Intravitreal Use via SUSVIMO ocular implant.

The SUSVIMO initial fill and ocular implant insertion and implant removal procedures must be performed under aseptic conditions by a physician experienced in vitreoretinal surgery. The SUSVIMO ocular implant must be surgically implanted in the eye or removed from the eye (if medically necessary) in an operating room using aseptic technique. See SUSVIMO Instructions for Use and the standardized steps to optimize surgical outcomes.

SUSVIMO refill-exchange procedures must be performed under aseptic conditions by a physician experienced in ophthalmic surgery *[see Dosage and Administration (2.7)]*.

Do not administer SUSVIMO (ranibizumab injection) as a bolus intravitreal injection. Do not substitute SUSVIMO (ranibizumab injection) with other ranibizumab products.

Initial Fill: One SUSVIMO initial fill needle (34-gauge, with integrated 5 µm filter and blue cap) is included. A 5-micron sterile filter needle (19-gauge x 1½ inch), and a 1 mL Luer lock syringe are needed but **not included**.

Refill-Exchange: One SUSVIMO refill needle (34-gauge with integrated 5 µm filter and clear cap) is included. A 5-micron sterile filter needle (19-gauge x 1½ inch), and a 1 mL Luer lock syringe are needed but **not included**.

2.2 Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)

The recommended dose of SUSVIMO (ranibizumab injection) is 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the SUSVIMO ocular implant with refills administered every 24 weeks (approximately 6 months).

2.3 Diabetic Retinopathy (DR)

The recommended dose of SUSVIMO (ranibizumab injection) is 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the SUSVIMO ocular implant with refills administered every 36 weeks (approximately 9 months).

2.4 Supplemental Treatment with Intravitreal Ranibizumab Injection

Supplemental treatment with 0.5 mg (0.05 mL of 10 mg/mL) intravitreal ranibizumab injection may be administered in the affected eye while the SUSVIMO implant is in place and if clinically necessary [see *Clinical Studies (14)*].



2.5 Ocular Implant Initial Fill

The implant initial fill procedure must be performed by a physician experienced in vitreoretinal surgery [see *Dosage and Administration (2.1)*]. The implant will be filled using aseptic technique with 0.02 mL of SUSVIMO (ranibizumab injection) prior to insertion of the implant into the patient's eye [see *Dosage and Administration (2.6)*].

Refer to the complete SUSVIMO Instructions for Use for the initial fill and implant procedure included in the insertion tool assembly carton for further details.

Use aseptic technique to carry out the following preparation steps prior to insertion of the ocular implant into the patient's eye:

Step 1: Gather the supplies needed. • One SUSVIMO ocular implant with insertion tool assembly (included) • One SUSVIMO initial fill needle (34-gauge with integrated 5 µm filter) with blue cap (included) • One SUSVIMO (ranibizumab injection) 100 mg/mL vial (included) • One sterile 5-micron filter needle (19-gauge x 1½ inch) (not included)	
---	--

One sterile 1 mL Luer Lock syringe (not included)	
Step 2: Transfer Dose from Vial to Syringe Note: Use the filter needle (not included) to withdraw SUSVIMO (ranibizumab injection) from the vial. Do not use the SUSVIMO initial fill needle for this step. - Prepare SUSVIMO (ranibizumab injection) vial by removing the flip-off cap and disinfecting the rubber vial septum with alcohol. - Attach a filter needle to the syringe by screwing it tightly onto the Luer lock (see Figure 1). - Carefully remove the needle cap by pulling it straight off. - Using aseptic technique, withdraw all of the contents of the SUSVIMO (ranibizumab injection) vial through the filter needle into the syringe.	 Figure 1
Step 3: Remove Air from Syringe - With the filter needle attached, hold the syringe with the needle pointing up. - If there are any air bubbles, gently tap the syringe with your finger until the bubbles rise to the top (Figure 2). - Slowly push the plunger rod just until all air is expelled from the syringe and needle. - It is important to preserve as much drug as possible in order to completely fill the implant. - Remove and properly dispose of the filter needle after air is removed from syringe.	 Figure2

Step 4: Attach SUSVIMO Initial Fill Needle

Do not use the filter needle to fill the implant.

- Attach the SUSVIMO initial fill needle (included) firmly onto the syringe by screwing it tightly onto the Luer lock (see Figure 3). Ensure that the initial fill needle is attached to the syringe.
- Carefully remove the needle cap by pulling straight off.
- **Do not** wipe the needle at any time.




Figure 3

Step 5: Remove Any Remaining Air from Syringe

- With the initial fill needle attached, hold the syringe with the needle pointing up. If there are any air bubbles, gently tap the syringe with your finger until the bubbles rise to the top (see Figure 4).
- Slowly push the plunger rod just until all air is expelled from the syringe and needle, and a drop of drug solution is seen at the needle tip (see Figure 5).

Note: It is important to preserve as much drug as possible in order to completely fill the implant.




Figure 4




Figure 5

Step 6: Inspect the Syringe for Air Bubbles

- Inspect the syringe and the needle hub to ensure that no air bubbles are present (see Figure 6).
- If air bubbles are present, continue to remove air from the syringe and reinspect.

Note: Use the syringe within **15 minutes** of removing all air to avoid ranibizumab drying in the needle and impeding fluid flow.

Do not use the initial fill needle if the needle is clogged.




Figure 6

Step 7: Load Syringe into the Carrier

Do not hold or push on the plunger rod of the syringe while inserting the needle into the implant septum.

- Retrieve insertion tool carrier with pre-positioned implant from the inner tray.
- Align the syringe Luer lock above the Luer lock slot in the carrier to protect the needle from being damaged.
- Lower the syringe into the carrier (see Figure 7).
- Push the syringe forward until it stops, taking care to avoid touching the plunger rod (see Figure 8)




Figure 7: Align and lower the syringe into the carrier

- With the syringe loaded, (see Figure 9) the initial fill needle should now be penetrating the implant septum.




Figure 8: Push the syringe into the carrier




Figure 9: Syringe with initial fill needle inserted through the implant septum

Step 8: Fill Ocular Implant with SUSVIMO (ranibizumab injection) Under Microscope

- Under the microscope, **slowly** administer SUSVIMO (ranibizumab injection) into the ocular implant by slightly tilting the carrier upwards (see Figure 10).
- The ocular implant should be filled over approximately **5 to 10 seconds**, to help avoid air entrapment in the implant reservoir.

Note: When filling the ocular implant, drug solution should only exit the ocular implant from the release control element. If drug solution is leaking from the implant at a different location, such as the side of the implant, **do not** use the ocular implant. If fluid is leaking from the septum at the needle insertion site, the needle may not be fully penetrating the implant septum. Fully push the syringe forward




Figure 10: Administer ranibizumab into the implant

before continuing to fill the ocular implant.

- Continue filling the ocular implant until the implant is completely full of drug solution and all air has been expelled as evidenced by a dome of drug solution formed at the tip of the implant on the release control element (see Figure 11).




Figure 11: Dome of drug solution forms at tip of implant as viewed under magnification

Step 9: Inspect the Filled Ocular Implant Under the Microscope

- Inspect the ocular implant under the microscope to ensure that the ocular implant is completely full of drug solution (see Figure 12).

Note: Minimize air bubbles within the implant reservoir as they may cause slower drug release. If an air bubble is present, it must be no larger than 1/3 of the widest diameter of the implant. If excess air is observed, **do not** use the ocular implant.

Note: No more than 30 minutes should pass between the initial fill of the implant and the insertion into the patient's eye to ensure that the release control element remains saturated with SUSVIMO (ranibizumab injection). If SUSVIMO (ranibizumab injection) dries in the release control element, the implant may not release the drug properly into the vitreous after insertion.




Figure 12: Proper appearance of implant after initial filling with ranibizumab

Step 10: Remove the Syringe and Guide Sleeve from the Carrier

- Remove the syringe and guide sleeve from the carrier by pulling back on the syringe (see Figure 13). The syringe will be locked into the guide sleeve.
- Properly dispose of the used syringe together with the needle and guide sleeve in a sharps disposal container or in accordance with local requirements.




Figure 13: Remove the syringe and guide sleeve from the insertion tool carrier

Step 11: Slide the Insertion Tool Handle into the Carrier

- Slide the insertion tool handle into the guide channel of the carrier, ensuring that both components are facing upwards (see Figure 14).
- Push the handle forward as far as it will go into the gripper tips (see Figure 15).

Note: Do not withdraw the handle and implant until the eye is ready for insertion. Contact between the implant and any surface or object – even within the sterile field – may result in the introduction of a foreign body into the vitreous.




Figure 14: Insert the handle into the insertion tool carrier




Figure 15: Fully inserted handle

2.6 Ocular Implant Insertion

SUSVIMO ocular implant insertion is a surgical procedure that is performed in an operating room. The procedure must be performed under aseptic conditions by a physician experienced in vitreoretinal surgery [see *Dosage and Administration (2.1)*].

The ocular implant is filled with SUSVIMO (ranibizumab injection) immediately prior to insertion. **No more than 30 minutes should pass between the initial fill of the ocular implant and the insertion into the patient's eye.**

After placing an infusion line in the eye, create at least a 6x6 mm peritomy of the conjunctiva and Tenon's capsule centered around the selected SUSVIMO implant location in the supero-temporal quadrant. Perform careful conjunctival incision, hemostasis of the underlying sclera, and generous undermining of Tenon's capsule. Using aseptic technique, fill the ocular implant [see *Dosage and Administration (2.5)*]. Using an MVR blade, create a full thickness dissection of the sclera 4 mm from the limbus until the pars plana is fully visible, with final target scleral incision length of 3.5 mm. Using a 532 nm laser endoprobe, apply contiguous, overlapping laser spots starting at 300 mW 1000 ms along the full length of the exposed pars plana and repeat until complete ablation is achieved. Pass a 3.2 mm slit knife perpendicularly through the center of the scleral dissection to open the underlying pars plana. Use the insertion tool to slowly insert the SUSVIMO implant into the sclero-pars plana incision perpendicular to the globe, ensuring that the long axis of the implant flange is properly aligned with the sclero-pars plana incision. Using the closed gripper tips of the insertion tool, seat the implant flush against the sclera. Clean any residual vitreous around the implant flange using a vitrector. Suture both Tenon's capsule and conjunctiva, using scleral anchoring at the apex of the peritomy,

ensuring complete coverage of the implant flange. Refer to the complete SUSVIMO Instructions for Use for the initial fill and implant procedure included in the insertion tool assembly carton for further details.

2.7 Ocular Implant Removal

Removal of the SUSVIMO ocular implant is a surgical procedure that is performed in an operating room. The procedure must be performed under aseptic conditions by a physician experienced in vitreoretinal surgery [see *Dosage and Administration (2.1)*].

After placing an infusion line in the eye, create at least a 6x6 mm peritomy of the conjunctiva and Tenon's capsule around the SUSVIMO ocular implant flange. Remove any fibrous capsule or scar tissue that may have formed over the implant flange and septum using scalpel and forceps. With the explant tool oriented perpendicular to the globe, align the contoured tips with the long axis of the implant flange and grasp underneath the implant flange. Once the implant is secured in the explant tool, pull the implant from the eye in a perpendicular motion. Clear any vitreous prolapse present within or around the scleral wound using a vitrector. Completely close the scleral incision with multiple non-absorbable sutures. Close the Tenon's capsule and conjunctiva to completely cover the scleral incision. Refer to the complete Instructions for Use for the implant removal procedure included in the explant tool carton for further details.


2.8 Ocular Implant Refill-Exchange Procedure


The SUSVIMO ocular implant refill-exchange procedure must be performed under strict aseptic conditions by a physician experienced in ophthalmic surgery [see *Dosage and Administration (2.1)*]. This includes the use of a surgical mask, sterile gloves, and a lid speculum.


Prior to and after the refill-exchange procedure, perform a dilated slit lamp exam and/or dilated indirect ophthalmoscopy to inspect the implant in the vitreous cavity through the pupil to identify if dislodgement of the implant septum has occurred [see *Figure 33 and Warnings and Precautions (5.4)*].

If the septum has dislodged, any further refill-exchange procedures should not be performed because normal device functioning cannot be assured. Discontinue treatment with SUSVIMO (ranibizumab injection) following septum dislodgement and consider implant removal should the benefit of the removal procedure outweigh the risk.

Step 1: Gather the supplies needed. • One SUSVIMO Refill Needle (34-gauge with a 5 µm integrated filter) with clear cap (included) • One SUSVIMO (ranibizumab injection) 100 mg/mL vial (included) • One sterile 1 mL Luer Lock syringe (not included) • One sterile 5-micron filter needle (19-gauge x 1½ inch) (not included)	
---	--

Additional materials required to perform the procedure but are not provided are: • Anesthetic ophthalmic solutions • Ophthalmic broad-spectrum microbicide solution • Cotton tips and gauze • Sterile powder free gloves • Face masks • Lid speculum • Magnification such as visor or loupes • Task lighting • Indirect ophthalmoscope and lens • Sterile drape (<i>optional for refill-exchange procedure</i>)	
Step 2: Inspect Packaging and Components • Prior to use in the clinic, inspect the packaging of the components for damage. Do not use if the sterility has been compromised or the contents have been dropped, damaged, or tampered with. • Check the expiration date printed on the label. • Remove the vial from the carton. <u>Note</u>: the outside of the vial is not sterile. • <u>Use aseptic technique</u> to open packaging and remove the <u>sterile refill needle</u> from the tray. • Inspect components and place onto sterile field (see Figure 16).	 Figure 16
Step 3: Inspect SUSVIMO (ranibizumab injection) • Visually inspect the contents of the SUSVIMO (ranibizumab injection) vial for particulate matter and discoloration. • SUSVIMO should be colorless to slightly brownish Do not use if particulate, cloudiness, or discoloration are visible.	

Step 4: Patient Preparation • Dilate the pupil of the eye. • Perform slit lamp examination and/or indirect ophthalmoscopy to inspect the implant and its components in the vitreous cavity through the dilated pupil. • Position the patient on exam chair in the supine position at approximately 20° to 30° angle for optimal visualization of the implant. • Apply a broad-spectrum microbicide to the periocular skin, eyelid, and ocular surface prior to the refill-exchange procedure. The use of a sterile drape is up to the physician's discretion. • Perform the procedure under topical anesthesia. • If needed, subconjunctival anesthesia may be administered in the nasal quadrant, away from the implant.	
Step 5: Transfer Dose from Vial to Syringe Note: Use the filter needle to withdraw SUSVIMO (ranibizumab injection) from the vial. Do not use the SUSVIMO refill needle for this step. • Prepare ranibizumab vial by removing the flip-off cap and disinfecting the rubber vial septum with alcohol. • Attach a filter needle to the syringe by screwing it tightly onto the Luer lock (see Figure 17). • Carefully remove the needle cap by pulling it straight off. • Using aseptic technique, withdraw all of the contents of the SUSVIMO	 Figure 17

(ranibizumab injection) vial through the filter needle into the syringe.	
Step 6: Remove Air from Syringe • With the filter needle attached, hold the syringe with the needle pointing up. • If there are any air bubbles, gently tap the syringe with your finger until the bubbles rise to the top (Figure 18). • Slowly push the plunger rod just until the air is expelled from the syringe and needle. – It is important to preserve as much drug as possible in order to completely refill the implant • Remove and properly dispose of the filter needle after air is removed from the syringe.	 Figure 18
Step 7: Attach SUSVIMO Refill Needle Do not use the filter needle to fill the implant. • Attach the SUSVIMO refill needle firmly onto the syringe by screwing it tightly onto the Luer lock (see Figure 19). Ensure that the refill needle is attached to the syringe. • Carefully remove the needle cap, pulling straight off to avoid damage to the needle cannula. • Do not wipe the needle at any time.	 Figure 19

Step 8: Remove Any Remaining Air from Syringe and Adjust Drug Dose

- With the refill needle attached, hold the syringe with the needle pointing up.
- If there are any air bubbles, gently tap the syringe with your finger until the bubbles rise to the top (see Figure 20).
- Slowly push the plunger rod until all air is expelled from the syringe and needle and the uppermost edge of the black plunger tip is aligned with the **0.1 mL** dose mark (see Figure 21).




Figure 20




Figure 21

Step 9: Inspect the Syringe for Air Bubbles

Note: Ensure no air bubbles are present in the syringe and needle hub. Air injected into the implant could result in slower drug release.

- Inspect the syringe and the needle hub using magnification to ensure that no air bubbles are present (see Figure 22).

Note: Use the syringe within **15 minutes** of removing all air and adjusting the drug




Figure 22

dose to avoid drug solution drying in the needle and impeding fluid flow. Do not use the refill needle or syringe if the needle is clogged.	
Step 10: Stabilize the globe and orient the refill needle Note: Perform the refill-exchange procedure using magnification (e.g., loupes, reading glasses, magnifiers) for visual assistance. • After placing the lid speculum in the eye, stabilize the globe with a cotton-tipped applicator to minimize eye movement (see Figure 23). – Recommend standing on the contralateral side of the implanted eye, with the patient looking down and toward their nose to optimally expose the implant. • Orient the refill needle perpendicular to the globe (see Figure 24).	Figure 23 Figure 24

Step 11: Insert the Refill Needle

Note: Insert needle at the very center of the implant septum and perpendicular to the implant to ensure the needle inserts fully. **Do not** maneuver if there is resistance as it will bend the needle.

Do not use a bent refill needle; replace if bent or if damage is suspected.

- Targeting the center of the implant septum, insert the refill needle perpendicularly through the conjunctiva and into the implant septum (see Figure 25).
 - If excessive resistance, withdraw the refill needle. Orient and insert again.
 - **Do not** twist when encountering conjunctiva and Tenon's capsule to gain access to the septum, as damage to the overlying tissue and to the septum of the device may result.
- Continue inserting the needle until the soft stop of the refill needle makes physical contact with the conjunctiva (see Figure 26) to provide a tactile cue that optimal contact has been made.




Figure 25




Figure 26

Step 12: Refill the SUSVIMO Implant

- Refill the implant **slowly**, by delivering the entire contents of the syringe into the implant, over approximately **5 to 10 seconds**, to avoid pressure build-up in the implant reservoir. The soft stop of the refill needle must remain in contact with the conjunctiva throughout the procedure.
- As ranibizumab is administered into the implant, existing solution from the implant should immediately begin to fill the refill needle fluid collection chamber (see Figure 27).





Figure 27

• If fluid is not observed collecting in the refill needle fluid collection reservoir, stop injecting and ensure the refill needle is inserted into the center of the implant septum at a perpendicular angle and the soft stop is in contact with the conjunctiva. • Administer all of the syringe contents in order to achieve the target replacement ranibizumab concentration in the implant reservoir.	
Step 13: Withdraw the Syringe • Withdraw the syringe perpendicular to the globe to avoid damaging the septum (see Figure 28). • A cotton-tipped applicator may be used to provide counter traction to the conjunctiva during needle withdrawal.	 Figure 28
Step 14: Dispose of the Used Components • Do not recap the needle or detach it from the syringe. Dispose of the used syringe together with the refill needle in a sharps disposal container or in accordance with local requirements.	
Step 15: Perform Indirect Ophthalmoscopy • Perform dilated indirect ophthalmoscopy (and slit lamp exam as needed) to ensure continued proper position of the implant and its components (e.g., septum) in the vitreous cavity and to examine for complications.	

2.9 Delayed or Missed Doses

For patients with AMD or DME, if a planned dose (refill-exchange) of SUSVIMO (ranibizumab injection) is missed, it should be administered as soon as possible and the subsequent refill-exchange procedures should be performed 24 weeks (approximately 6 months) thereafter.

For patients with DR, if a planned dose (refill-exchange) of SUSVIMO (ranibizumab injection) is missed, it should be administered as soon as possible and the subsequent refill-exchange procedures should be performed 36 weeks (approximately 9 months) thereafter.

2.10 Dosage (Refill-Exchange) Modifications for Adverse Reactions

Table 1 describes dosage modifications for specific adverse Reactions [see *Warnings and Precautions (5)*]. No dosage reductions for SUSVIMO are recommended.

Table 1: Dosage (Refill-Exchange) Modifications for Adverse Reactions

Adverse Reactions	Dosage Modification
Intraocular inflammation ≥ 1 + cells or flare	Withhold dose (refill-exchange)
Sight threatening events (e.g., rhegmatogenous retinal detachment, vitreous hemorrhage, unexplained vision loss, etc.)	Withhold dose (refill-exchange)
Local infections of either eye	Withhold dose (refill-exchange)
Infectious endophthalmitis	Withhold dose (refill-exchange)
Severe systemic infection	Withhold dose (refill-exchange)
Observed damage to the implant	Withhold dose (refill-exchange) and consider SUSVIMO implant removal [see <i>Dosage and Administration (2.8, 2.9)</i>].

3 DOSAGE FORMS AND STRENGTHS

Injection: 100 mg/mL, clear to slightly opalescent, colorless to slightly brownish solution in a single-dose vial

4 CONTRAINDICATIONS

4.1 Ocular or Periocular Infections

SUSVIMO (ranibizumab injection) is contraindicated in patients with ocular or periocular infections.

4.2 Active Intraocular Inflammation

SUSVIMO (ranibizumab injection) is contraindicated in patients with active intraocular inflammation.

4.3 Hypersensitivity

SUSVIMO (ranibizumab injection) is contraindicated in patients with known hypersensitivity to ranibizumab products or any of the excipients in SUSVIMO (ranibizumab injection).

5 WARNINGS AND PRECAUTIONS

The SUSVIMO implant and/or implant-related procedures have been associated with endophthalmitis, rhegmatogenous retinal detachment, implant dislocation, septum dislodgement, vitreous hemorrhage, conjunctival erosion, conjunctival retraction, and conjunctival blebs. Patients should be instructed to report any signs or symptoms that could be associated with these events without delay. In some cases, these events can present asymptotically. The implant and

the tissue overlying the implant flange should be monitored routinely following the implant insertion, and refill-exchange procedures to permit early medical or surgical intervention as necessary. Special precautions need to be taken when handling SUSVIMO components [*see How Supplied/Storage and Handling (16.3)*].

5.1 Endophthalmitis

In the active comparator period of controlled clinical trials in AMD, the ranibizumab implant has been associated with a 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab (1.7% in the SUSVIMO arm vs 0.5% in the intravitreal arm). When including extension phases of clinical trials, 2% (11/555) of patients receiving the ranibizumab implant experienced an episode of endophthalmitis. Reports occurred between days 5 and 853, with a median of 173 days. Many, but not all, of the cases of endophthalmitis reported a preceding or concurrent conjunctival retraction or erosion event.

In the active comparator period of the controlled clinical trial in DME, 0% of patients in the SUSVIMO arm compared to 0.3% in the intravitreal arm experienced an episode of endophthalmitis. When including the extension phase of the clinical trial, 0.7% (4/556) of patients receiving the ranibizumab implant experienced an episode of endophthalmitis. Reports occurred between days 625 and 1016, with a median of 824 days.

In the period with an observational comparator arm of the clinical trial in DR, there were no patients (0/105) in the SUSVIMO arm who experienced an episode of endophthalmitis [*see Clinical Studies (14.3)*]. When including the extension phase of the clinical trial 0.8% (1/128) patients receiving the ranibizumab implant experienced an episode of endophthalmitis, with the event reported on day 695.

Endophthalmitis should be treated promptly in an effort to reduce the risk of vision loss and maximize recovery. The SUSVIMO (ranibizumab injection) dose (refill-exchange) should be delayed until resolution of endophthalmitis [*see Dosage and Administration (2.10) and Adverse Reactions (6.1)*].

Patients should not have an active or suspected ocular or periocular infection or severe systemic infection at the time of any SUSVIMO implant or refill procedure. Appropriate intraoperative handling followed by secure closure of the conjunctiva and Tenon's capsule, and early detection and surgical repair of conjunctival erosions or retractions and strict/controlled aseptic technique conditions throughout refill-exchange procedures may reduce the risk of endophthalmitis [*see Dosage and Administration (2.1) and Warnings and Precautions (5.5)*].

5.2 Rhegmatogenous Retinal Detachment

Rhegmatogenous retinal detachments have occurred in clinical trials of SUSVIMO and may result in vision loss. Rhegmatogenous retinal detachments should be promptly treated with an intervention (e.g., pneumatic retinopexy, vitrectomy, or laser photocoagulation). SUSVIMO (ranibizumab injection) dose (refill-exchange) should be delayed in the presence of a retinal detachment or retinal break [*see Dosage and Administration (2.10)*].

Careful evaluation of the retinal periphery is recommended to be performed, and any suspected areas of abnormal vitreo-retinal adhesion or retinal breaks should be treated before inserting the implant in the eye.

5.3 Implant Dislocation

In clinical trials, the device has dislocated/subluxated into the vitreous cavity or has extended outside the vitreous cavity into or beyond the subconjunctival space. Device dislocation requires urgent surgical intervention. Strict adherence to the scleral incision length and appropriate targeting of the pars plana during laser ablation may reduce the risk of implant dislocation.

5.4 Septum Dislodgement

In clinical trials, a type of implant damage where the septum has dislodged into the implant body has been reported. Perform a dilated slit lamp exam and/or dilated indirect ophthalmoscopy to inspect the implant in the vitreous cavity through the pupil prior to and after the refill-exchange procedure to identify if septum dislodgement has occurred. Discontinue treatment with SUSVIMO (ranibizumab injection) following septum dislodgement and consider implant removal should the benefit of the removal procedure outweigh the risk [see *Dosage and Administration* (2.9)]. The benefits and risks of retaining, removing, or removing and replacing an implant with a dislodged septum are not well characterized.

Appropriate handling and insertion of the refill needle into the septum (avoid twisting and/or rotation) is required to minimize the risk of septum dislodgement [see *Dosage and Administration* (2.8)].

5.5 Vitreous Hemorrhage

Vitreous hemorrhages may result in temporary vision loss. Vitrectomy may be needed in the case of a non-clearing vitreous hemorrhage [see *Dosage and Administration* (2.10)].

In clinical trials of SUSVIMO including the extension phases in patients with AMD, vitreous hemorrhages were reported in 5.2% (23/443) of patients receiving SUSVIMO.

In the clinical trial of SUSVIMO including the extension phases in patients with DME, vitreous hemorrhages were reported in 10.1% (56/556) of patients receiving SUSVIMO.

In the clinical trial of SUSVIMO including the extension phase in patients with DR, vitreous hemorrhages were reported in 9.4% (12/128) of patients receiving SUSVIMO.

The majority of these hemorrhages occurred within the first post-operative month following surgical implantation and the majority of vitreous hemorrhages resolved spontaneously.

Patients on antithrombotic medication (e.g., oral anticoagulants, aspirin, nonsteroidal anti-inflammatory drugs) may be at increased risk of vitreous hemorrhage. Antithrombotic medications are recommended to be temporarily interrupted prior to the implant insertion procedure. The SUSVIMO (ranibizumab injection) dose (refill-exchange) should be delayed in the event of sight-threatening vitreous hemorrhage. The use of pars plana laser ablation and scleral cauterization should be performed to reduce the risk of vitreous hemorrhage.

5.6 Conjunctival Erosion or Retraction

A conjunctival erosion is a full thickness degradation or breakdown of the conjunctiva in the area of the implant flange. A conjunctival retraction is a recession or opening of the limbal and/or radial peritomy. Conjunctival erosions or retractions have been associated with an increased risk of endophthalmitis, especially if the implant becomes exposed. Surgical intervention (e.g., conjunctival/Tenon's capsule repair) is recommended to be performed in case of conjunctival erosion or retraction with or without exposure of the implant flange.

In clinical trials of SUSVIMO including the extension phases in patients with AMD, 3.6% (16/443) of patients receiving SUSVIMO reported conjunctival erosion and 1.6% (7/443) of patients receiving SUSVIMO reported conjunctival retraction in the study eye.

In the clinical trial of SUSVIMO including the extension phases of patients with DME, 2.2% (12/556) of patients receiving SUSVIMO reported conjunctival erosion and 1.3% (7/556) of patients receiving SUSVIMO reported conjunctival retraction in the study eye.

In the clinical trial of SUSVIMO including the extension phase in patients with DR, 2.3% (3/128) of patients receiving SUSVIMO reported conjunctival erosion and 1.6% (2/128) of patients receiving SUSVIMO reported conjunctival retraction in the study eye.

Appropriate intraoperative handling of conjunctiva and Tenon's capsule to preserve tissue integrity and secure closure of peritomy while ensuring placement of sutures away from implant edge may reduce the risk of conjunctival erosion or retraction. The implant and the tissue overlying the implant flange should be monitored routinely following the implant insertion.

5.7 Conjunctival Bleb

A conjunctival bleb is an encapsulated elevation of the conjunctiva above the implant flange, which may be secondary to subconjunctival thickening or fluid. Conjunctival blebs may require surgical management to avoid further complications, especially if the implant septum is no longer identifiable due to the conjunctival bleb.

In clinical trials of SUSVIMO including the extension phases in patients with AMD, 5.9% (26/443) of patients receiving SUSVIMO reported conjunctival bleb/conjunctival filtering bleb leak in the study eye.

In the clinical trial of SUSVIMO including the extension phases in patients with DME, 9% (50/556) of patients receiving SUSVIMO reported conjunctival bleb/conjunctival filtering bleb leak in the study eye.

In the clinical trial of SUSVIMO including the extension phase in patients with DR, 3.9% (5/128) of patients receiving SUSVIMO reported conjunctival bleb/conjunctival filtering bleb leak in the study eye.

Strict adherence to the scleral incision length, appropriate intraoperative handling of conjunctiva and Tenon's capsule to preserve tissue integrity and secure closure of peritomy, and proper

seating of the refill needle during refill-exchange procedures may reduce the risk of conjunctival bleb.

5.8 Postoperative Decrease in Visual Acuity

Visual acuity was decreased by 4 letters on average in the first postoperative month and 2 letters on average in the second postoperative month following initial implantation of SUSVIMO in patients with AMD [see *Clinical Studies (14.1)*].

Visual acuity was decreased by 7 letters on average in the first postoperative month and 3 to 4 letters on average in the second postoperative month following initial implantation of SUSVIMO in patients with DME and DR [see *Clinical Studies (14.2 and 14.3)*].

5.9 Postoperative Intraocular Inflammation

Postoperative intraocular inflammation has occurred following SUSVIMO implantation. The majority of cases occurred during the first week following implantation and resolved within the first month.

5.10 Air Bubbles Causing Improper Filling of the Implant

Minimize air bubbles within the implant reservoir as they may cause slower drug release. During the initial fill procedure, if an air bubble is present, it must be no larger than 1/3 of the widest diameter of the implant. If excess air is observed after initial fill, **do not** use the implant. During the refill-exchange procedure, if excess air is present in the syringe and needle **do not** use the syringe and needle. If excess air bubbles are observed after the refill-exchange procedure, consider repeating the refill-exchange procedure.

5.11 Deflection or Movement of the Implant

Use caution when performing ophthalmic procedures (e.g., B-scan ophthalmic ultrasound, scleral depression, or gonioscopy) that may cause deflection or movement of the implant and subsequent injury.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the label:

- Endophthalmitis [see *Warnings and Precautions (5.1)*]
- Rhegmatogenous Retinal Detachment [see *Warnings and Precautions (5.2)*]
- Implant Dislocation [see *Warnings and Precautions (5.3)*]
- Septum Dislodgement [see *Warnings and Precautions (5.4)*]
- Vitreous Hemorrhage [see *Warnings and Precautions (5.5)*]
- Conjunctival Erosion or Retraction [see *Warnings and Precautions (5.6)*]
- Conjunctival Bleb [see *Warnings and Precautions (5.7)*]
- Postoperative Decrease in Visual Acuity [see *Warnings and Precautions (5.8)*]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice.

The data below (Table 2) reflect exposure of 248 patients with AMD in the Archway study through Week 40, 320 patients with DME in the Pagoda study up to Week 64, and 105 patients with DR in the Pavillion study through Week 52 following the SUSVIMO initial fill and implant insertion, refill, and implant removal (if necessary) procedures.

In clinical trials of SUSVIMO in AMD patients, the most common ($\geq 10\%$) adverse reactions up to Week 40 were conjunctival hemorrhage (72%), conjunctival hyperemia (26%), iritis (23%), and eye pain (10%). Septum dislodgement was reported in 0.4% of the AMD patient population.

In clinical trials of SUSVIMO in DME patients, patient population the most common ($\geq 10\%$) adverse reactions up to Week 64 were conjunctival hemorrhage (62%), conjunctival hyperemia (15%), iritis (14%), eye pain (13%), cataract (11%), conjunctival disorder (10%) and vitreous hemorrhage (10%).

In clinical trials of SUSVIMO in DR patients, the most common ($\geq 10\%$) adverse reactions up to Week 52 were conjunctival hemorrhage (73%), conjunctival disorder (14%), iritis (12%) and conjunctival hyperemia (11%).

Table 2 Adverse Reactions occurring in $\geq 4\%$ of patients in the SUSVIMO arm

Adverse Reactions	AMD Week 40		DME Week 64		DR Week 52
	SUSVIMO n = 248	Intravitreal ranibizumab n = 167	SUSVIMO n = 320	Intravitreal ranibizumab 0.5 mg n = 314	SUSVIMO n = 105
Conjunctival hemorrhage	72%	6%	62%	18%	73%
Conjunctival hyperemia	26%	2%	15%	0	11%
Iritis ¹	23%	0.6%	14%	2%	12%
Eye pain	10%	5%	13%	6%	9%
Conjunctival disorder ²	9%	0	10%	0.3%	14%
Vitreous floaters	9%	2%	4%	5%	2%
Conjunctival bleb/ filtering bleb leak ³	8%	0	8%	0	2%
Foreign body sensation in eyes	7%	1%	3%	2%	9%
Headache ⁴	6%	2%	6%	4%	9%
Hypotony of eye	6%	0	3%	0	0

Adverse Reactions	AMD Week 40		DME Week 64		DR Week 52
	SUSVIMO n = 248	Intravitreal ranibizumab n = 167	SUSVIMO n = 320	Intravitreal ranibizumab 0.5 mg n = 314	SUSVIMO n = 105
Vitreous detachment	6%	5%	8%	5%	9%
Vitreous hemorrhage	5%	2%	10%	2%	6%
Cataract ⁵	4%	4%	11%	7%	7%
Corneal disorder	4%	0	1%	0	1%
Corneal abrasion ⁶	4%	0.6%	4%	1%	4%
Corneal edema	4%	0	4%	0.3%	4%

¹ Iritis includes: iritis, anterior chamber flare, anterior chamber inflammation, and anterior chamber cell.

² Conjunctival disorder includes: conjunctival adhesion, conjunctival disorder, conjunctival edema, conjunctival erosion, conjunctival retraction, and subconjunctival fibrosis.

³ Conjunctival bleb/filtering bleb leak includes: conjunctival bleb, conjunctival filtering bleb leak, conjunctival cyst, subconjunctival cyst, and implant site cyst.

⁴ Headache includes: headache and procedural headache.

⁵ Cataract includes: cataract, cortical cataract, nuclear cataract, and subcapsular cataract.

⁶ Corneal abrasion includes: corneal abrasion and vital dye staining cornea present.

In clinical trials of SUSVIMO, hyphema was reported in 0.4% of AMD patients, 1.9% of DME patients, and 1.9% of DR patients.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no adequate and well-controlled studies of SUSVIMO (ranibizumab injection) administration in pregnant women. Administration of ranibizumab to pregnant monkeys throughout the period of organogenesis resulted in a low incidence of skeletal abnormalities at intravitreal doses up to 41 times the human exposure (based on serum levels following the recommended clinical dose). No skeletal abnormalities were observed at serum trough levels similar to the human exposure after a single eye treatment at the recommended clinical dose (*see Data*).

Animal reproduction studies are not always predictive of human response, and it is not known whether ranibizumab can cause fetal harm when administered to a pregnant woman. Based on the anti-VEGF mechanism of action for ranibizumab [*see Clinical Pharmacology (12.1)*], treatment with SUSVIMO (ranibizumab injection) may pose a risk to human embryofetal development.

All pregnancies have a background risk of birth defects, loss, and other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects is 2% – 4% and of miscarriage is 15% – 20% of clinically recognized pregnancies.

Data

Animal Data

An embryo-fetal developmental toxicity study was performed on pregnant cynomolgus monkeys. Pregnant animals received intravitreal injections of ranibizumab every 14 days starting on Day 20 of gestation, until Day 62 at doses of 0, 0.125, and 1 mg/eye. Skeletal abnormalities including incomplete and/or irregular ossification of bones in the skull, vertebral column, and hindlimbs and shortened supernumerary ribs were seen at a low incidence in fetuses from animals treated with 1 mg/eye of ranibizumab. The 1 mg/eye dose resulted in trough serum ranibizumab levels up to 41 times higher than observed human $C_{\max}$ levels of SUSVIMO (ranibizumab injection) after treatment of a single eye.

No skeletal abnormalities were seen at the lower dose of 0.125 mg/eye, a dose which resulted in trough exposures similar to single eye treatment with SUSVIMO (ranibizumab injection) in humans. No effect on the weight or structure of the placenta, maternal toxicity, or embryotoxicity was observed.

8.2 Lactation

Risk Summary

There are no data available on the presence of ranibizumab in human milk, the effects of ranibizumab on the breastfed infant or the effects of ranibizumab on milk production/excretion. Because many drugs are excreted in human milk, and because the potential for absorption and harm to infant growth and development exists, caution should be exercised when SUSVIMO is administered to a nursing woman.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SUSVIMO (ranibizumab injection) and any potential adverse effects on the breastfed child from ranibizumab.

8.3 Females and Males of Reproductive Potential

Contraception

Females of reproductive potential should use effective contraception during treatment with SUSVIMO (ranibizumab injection) and for at least 12 months after the last dose of SUSVIMO (ranibizumab injection).

Infertility

No studies on the effects of ranibizumab on fertility have been conducted and it is not known whether ranibizumab can affect reproduction capacity. Based on the anti-VEGF mechanism of action for ranibizumab, treatment with SUSVIMO (ranibizumab injection) may pose a risk to reproductive capacity.

8.4 Pediatric Use

The safety and efficacy of SUSVIMO (ranibizumab injection) in pediatric patients have not been established.

8.5 Geriatric Use

In the Archway study, 90% (222 of 248) of the patients randomized to treatment with SUSVIMO were ≥ 65 years old and approximately 57% (141 of 248) were ≥ 75 years old. No notable difference in treatment effect or safety was seen with increasing age.

11 DESCRIPTION

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor-A (VEGF-A). Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by an *E. coli* expression system in a nutrient medium containing the antibiotic tetracycline. Tetracycline is not detectable in the final product.

SUSVIMO (ranibizumab injection) is supplied as a sterile, clear to slightly opalescent, colorless to slightly brownish solution for intravitreal use via the SUSVIMO implant. Each single-dose vial contains 10 mg of ranibizumab, histidine HCl (0.1 mg), polysorbate 20 (0.01 mg), sucrose (8.2 mg), and Water for Injection, in 0.1 mL of solution with a pH of 5.5. The SUSVIMO implant is designed to contain approximately 0.02 mL (2 mg) of ranibizumab solution when filled. SUSVIMO does not contain an antimicrobial preservative.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Ranibizumab binds to the receptor binding site of multiple biologically active forms of VEGF-A, including VEGF₁₁₀. VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.

12.3 Pharmacokinetics

The SUSVIMO implant provides a continuous release of ranibizumab where the release of ranibizumab into the vitreous decreases over time as the concentration in the implant decreases. The ranibizumab serum and aqueous humor concentrations with a SUSVIMO 24-week and 36-week treatment interval are maintained below the maximum and above the minimum concentrations experienced with monthly 0.5 mg intravitreal ranibizumab.

Distribution

Ranibizumab did not accumulate in serum when administered with refills every 24 weeks or every 36 weeks.

Following implant insertion of SUSVIMO in patients with AMD, the mean ($\pm$ SD) maximum ranibizumab serum concentration ($C_{\max}$) was 0.48 ($\pm$ 0.17) ng/mL and median (range) time to

maximum serum concentration ($T_{\max}$) was 26 (1 – 89) days. Following the initial fill and refill of SUSVIMO in patients, maximum serum concentrations of ranibizumab were below the ranibizumab concentration necessary to inhibit the biological activity of VEGF by 50%.

Elimination

Metabolism

The metabolism of SUSVIMO (ranibizumab injection) has not been studied. SUSVIMO (ranibizumab injection) is a monoclonal antibody fragment and antibodies are cleared principally by catabolism.

Excretion

The full excretion profile for ranibizumab following administration of SUSVIMO is unknown.

Specific Populations

Patients with renal impairment were included in the population pharmacokinetic analysis of SUSVIMO (ranibizumab injection). Across all indications, systemic clearance of ranibizumab was slightly lower in renally impaired patients but was not clinically significant. No clinically significant differences in the pharmacokinetics of ranibizumab were observed based on age in the patient population.

12.6 Immunogenicity

As with all therapeutic proteins, there is potential for immune response in patients treated with ranibizumab including SUSVIMO. The detection of an immune response is highly dependent on the sensitivity, specificity, and drug tolerance level of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the study described below with the incidence of antibodies in other studies or to other products may be misleading.

Prior to treatment with SUSVIMO, 2.1-3.6% of patients with AMD, DME, or DR tested positive for anti-ranibizumab antibodies. In patients with AMD, after the SUSVIMO implant insertion and treatment, 12% (29 of 247) patients tested positive for anti-ranibizumab antibodies. In patients with DME, after 4 doses of intravitreal ranibizumab, and SUSVIMO implant insertion and treatment, 13% (41 of 320) patients tested positive for anti-ranibizumab antibodies. In patients with DR, after 2 doses of intravitreal ranibizumab, and SUSVIMO implant insertion and treatment, 17% (17 of 99) patients tested positive for anti-ranibizumab antibodies. No clinically meaningful differences in the pharmacokinetics, efficacy, or safety in patients testing positive for anti-ranibizumab antibodies were observed.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No studies have been conducted to determine the carcinogenic or mutagenic potential of SUSVIMO (ranibizumab injection). Based on the anti-VEGF mechanism of action for ranibizumab, treatment with SUSVIMO (ranibizumab injection) may pose a risk to reproductive capacity [see *Females and Males of Reproductive Potential* (8.3)].

14 CLINICAL STUDIES

14.1 Neovascular (wet) Age-related Macular Degeneration (AMD)

The clinical efficacy and safety of SUSVIMO (ranibizumab injection) was assessed in a randomized, visual assessor-masked, active treatment-controlled study (Archway-NCT03677934) in patients with AMD. A total of 415 patients (248 in the SUSVIMO arm and 167 in the intravitreal ranibizumab arm) were enrolled and treated in this study. Patients were diagnosed with AMD within the 9 months prior to screening and received ≥ 3 doses of anti-VEGF intravitreal agents in the study eye within the last 6 months prior to screening. Each patient was required to have demonstrated a response to an anti-VEGF intravitreal agent prior to randomization. Patients were randomized in a 3:2 ratio to receive continuous delivery of SUSVIMO (ranibizumab injection) via the SUSVIMO implant every 24 weeks or 0.5 mg intravitreal ranibizumab injections every 4 weeks. For patients randomized to the SUSVIMO arm, supplemental treatment with 0.5 mg intravitreal ranibizumab injections was available at Weeks 16, 20, 40, 44, 64, 68, 88, and 92, if needed. In the first 24 weeks, 1.6% of patients assessed for supplemental treatment received 1 or more supplemental treatment(s) and in the following 24 weeks, 5.4% of patients assessed for supplemental treatment received 1 or more supplemental treatment(s).

The primary efficacy endpoint of change from baseline in distance Best Corrected Visual Acuity (BCVA) score averaged over Week 36 and Week 40 demonstrated that SUSVIMO was equivalent to intravitreal ranibizumab injections administered every 4 weeks. Detailed efficacy results are shown in Table 3 and Figure 29 below.

Table 3 Visual Acuity outcomes at Week 40 in Archway (GR40548) Study

Outcome Measure*	SUSVIMO (100 mg/mL) n=248	Intravitreal ranibizumab 0.5 mg (10 mg/mL) n=167	Difference (95% CI)**
Adjusted Mean change from baseline in BCVA score averaged over Weeks 36 and 40	0.2	0.5	-0.3 (-1.7, 1.1)***


BCVA = Best corrected visual acuity

*BCVA measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart at a starting distance of 4 meters.

**All estimates are adjusted estimates based on a mixed-effect model with repeated measures. SUSVIMO arm - intravitreal ranibizumab arm. 95% is a rounding of 95.03% CI; The type 1 error was adjusted for interim safety monitoring.

***Equivalence margins were ± 4.5 letters.

Figure 29 Adjusted Mean change from Baseline in Best Corrected Visual Acuity in study eye through Week 48 in the Archway (GR40548) study*, **



*Prior to study treatment, a median of 4 doses of anti-VEGF intravitreal agents were administered in the study eye of patients in the SUSVIMO and intravitreal ranibizumab arms.

**Decrease in BCVA at Week 4 during post-operative recovery period.

Q24W = every 24 weeks; Q4W = every 4 weeks

Consistent results were observed across patient subgroup analyses for mean change from baseline in BCVA score (age, gender, number of prior anti-VEGF intravitreal injections, and baseline BCVA score).

14.2 Diabetic Macular Edema (DME)

The clinical efficacy and safety of SUSVIMO were assessed in a randomized, visual assessor-masked, active treatment-controlled study (Pagoda-NCT04108156) in patients with DME. A total of 634 patients (381 in the SUSVIMO arm and 253 in the intravitreal ranibizumab 0.5 mg arm) were enrolled and treated in this study. Patients were randomized in a 3:2 ratio to receive continuous delivery of SUSVIMO via the implant every 24 weeks or 0.5 mg intravitreal ranibizumab injections every 4 weeks.

Prior to study treatment, a median of 4 doses of intravitreal ranibizumab 0.5 mg were administered in the study eye of patients in the SUSVIMO and intravitreal ranibizumab arms. Patient ages ranged from 29 to 89 years with a mean of 60.7 years. A total of 21% of patients were previously treated for DME. At baseline, the overall mean visual acuity was 65.3 letters (range: 25 to 89 letters).

The primary efficacy endpoint of change from baseline in distance Best Corrected Visual Acuity (BCVA) score averaged over Week 60 and Week 64 demonstrated that SUSVIMO was non-inferior to intravitreal ranibizumab injections administered every 4 weeks. Detailed efficacy results are shown in Table 4 and Figure 30 below.

Table 4 Key efficacy outcomes at Week 60 and Week 64 in the Pagoda (GR40550) Study


Outcome Measure*	SUSVIMO 100 mg/mL n=381	Intravitreal ranibizumab 0.5 mg (10 mg/mL) n=253	Difference (95% CI)**
Change in BCVA scores from baseline averaged over Week 60 and Week 64 Adjusted Mean	9.6	9.4	0.2 (-1.2, 1.6)

BCVA = Best corrected visual acuity

*BCVA measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart at a starting distance of 4 meters.

**All estimates are adjusted estimates based on a mixed-effect model with repeated measures. 95% is a rounding of 95.05% CI; The type 1 error was adjusted for interim safety monitoring.

Figure 30 Adjusted Mean change from Baseline in Best Corrected Visual Acuity in study eye through Week 64 in the Pagoda (GR40550) study



Consistent results were observed across patient subgroup analyses for mean change from baseline in BCVA score (age, ethnicity, gender, baseline HbA1c score, focal/macular laser history, baseline BCVA score, prior intravitreal anti-VEGF treatment and DR severity).

14.3 Diabetic Retinopathy (DR)

The clinical efficacy and safety of SUSVIMO were assessed in a randomized, visual assessor and reading center-masked study (Pavilion-NCT04503551) in patients with moderately-severe to

severe non-proliferative diabetic retinopathy (NPDR) [Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale (ETDRS-DRSS) of 47 or 53], without center-involved DME (CI-DME), and who had not received prior treatment in the study eye for DR. A total of 174 patients (106 in the SUSVIMO arm and 68 in the observational comparator arm) were enrolled in this study.

Patients who had not received prior treatment in the study eye for DR were randomized in a 5:3 ratio to continuous delivery of SUSVIMO via the implant every 36 weeks or to clinical observation. Prior to the implant procedure, two loading doses of intravitreal ranibizumab 0.5 mg were administered in the study eye. The observational comparator arm did not receive loading doses of intravitreal ranibizumab. For patients who developed CI-DME or proliferative diabetic retinopathy/anterior segment neovascularization in either arm, supplemental treatment with intravitreal injections of 0.5 mg ranibizumab was available per investigator's clinical judgment at any non-refill-exchange study visit. Patient ages ranged from 24 to 83 years with a mean of 53.9 years. At baseline, the overall mean visual acuity was 82.4 letters (range: 69 to 97 letters).

The primary efficacy endpoint was the proportion of patients with a ≥ 2 -step improvement on the ETDRS-DRSS from baseline at Week 52 versus clinical observation. SUSVIMO with two loading doses of intravitreal ranibizumab was superior to clinical observation at Week 52. Detailed results are shown in Table 5 and Figure 31 below.

Table 5 Efficacy Outcomes through Week 52 in the Pavilion (GR41675) Study


Outcome Measure	SUSVIMO 100 mg/mL (n=106)	Clinical Observation (n=68)	Difference 95% CI *
Adjusted proportion of patients with ≥ 2 -step improvement from baseline on the ETDRS-DRSS at Week 52	80%	9%	71% (61%, 81%)

ETDRS-DRSS = Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scores

CMH = Cochran-Mantel-Haenszel test

*All estimates are adjusted estimates based on the CMH method. 95% is a rounding of 95.04% CI; the type 1 error was adjusted for interim safety monitoring. $p < 0.01$ compared with clinical observation.

Figure 31 Adjusted Proportion of Patients with a ≥ 2 -Step Improvement from Baseline on ETDRS-DRSS in Study Eye over Time through Week 52 in the Pavilion (GR41675) Study



In the SUSVIMO arm, none of the patients assessed for supplemental treatment received any supplemental injections of intravitreal ranibizumab and 40% of patients in the observational comparator arm received 1 or more supplemental treatments through Week 52.

Consistent results were observed across patient subgroup analyses for ETDRS-DRSS score including age, race, ethnicity, baseline hemoglobin (HbA1c) and baseline ETDRS-DRSS score.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Each SUSVIMO initial fill needle kit (NDC 50242-078-55) contains:

- One SUSVIMO 100 mg/mL single-dose glass vial
- One SUSVIMO initial fill needle (34-gauge needle with a 5 μ m integrated filter) with a blue cap

Each SUSVIMO (ranibizumab injection) carton (NDC 50242-078-12) contains one SUSVIMO (ranibizumab injection) 100 mg/mL that is clear to slightly opalescent, colorless to slightly brownish solution in a single-dose glass vial.

Each SUSVIMO initial fill needle carton contains a SUSVIMO initial fill needle (34-gauge needle with a 5 μ m integrated filter) with a blue cap.

Each SUSVIMO refill needle carton contains a SUSVIMO refill needle (34-gauge vented needle with a 5 µm integrated filter) with a clear cap.

Device and Materials Description




Figure 32

SUSVIMO implant

- SUSVIMO implant (Figure 33) is capable of holding 0.02 mL of drug, and is secured within the sclera, by the extrascleral flange that remains visible through the conjunctiva following insertion.
- The septum is a self-sealing interface through which ranibizumab is administered to fill the implant.




Figure 33

SUSVIMO (ranibizumab injection) 100 mg/mL vial

- SUSVIMO (ranibizumab injection) (Figure 34) is used to fill the implant with ranibizumab prior to insertion or during subsequent refill-exchange in an office-based setting.



Figure 34

SUSVIMO refill needle

- SUSVIMO refill needle (Figure 35) consists of a 34 G vented needle assembly, silicone soft stop, and a 5 µm integrated filter within the needle hub. It is designed to simultaneously exchange the contents of the implant reservoir with replacement ranibizumab in an office-based setting. As replacement ranibizumab is administered into the implant through the stainless-steel cannula, fluid remaining in the implant flows through openings in the vented needle and is collected in the fluid collection reservoir.




Figure 35

- SUSVIMO refill needle is distinguished by its clear cap.

Materials List

Materials that are required and supplied to perform the procedure are:

- SUSVIMO refill needle, 34 G, with clear cap
- SUSVIMO (ranibizumab injection) 100 mg/mL

Additional materials required to perform the procedure but are not provided are:

- One sterile 1 mL Luer Lock syringe **(not included)**
- One sterile 5-micron filter needle (19-gauge x 1½ inch) **(not included)**
- Anesthetic ophthalmic solutions
- Ophthalmic broad-spectrum microbicide solution
- Cotton tips and gauze
- Sterile powder free gloves
- Face masks
- Lid speculum
- Magnification such as visor or loupes
- Task lighting
- Indirect ophthalmoscope and lens
- Sterile drape (*optional for refill-exchange procedure*)

16.2 Storage

Store SUSVIMO initial fill needle kit at 2°C to 8°C (36°F to 46°F). **Do not** freeze. Protect from light. **Do not** shake. The SUSVIMO initial fill needle has been sterilized with electron beam processing.

Store SUSVIMO (ranibizumab injection) 100 mg/ mL vial at 2°C to 8°C (36°F to 46°F). **Do not** freeze. Protect from light. **Do not** shake. Prior to use, the unopened vial may be kept at 9°C to 30°C (48°F to 86°F) for up to 24 hours provided it is protected from light.

Store the SUSVIMO implant and insertion tool assembly, refill needle and explant tool at room temperature 15°C to 25°C (59°F to 77°F). The SUSVIMO implant and insertion tool assembly has been sterilized with ethylene oxide gas. The SUSVIMO refill needle and explant tool has been sterilized with electron beam processing.

Store the SUSVIMO initial fill needle at 2°C to 25°C (36°F to 77°F). The SUSVIMO initial fill needle has been sterilized with electron beam processing.

16.3 Handling

SUSVIMO components are supplied sterile and are for single-use only. Do not reprocess, re-sterilize, or reuse SUSVIMO components. Do not use if the sterility has been compromised or the contents have been dropped, damaged or tampered with. Do not use past the expiration date printed on the label. Do not open sealed tray until time of use. Avoid contact between sharp surgical instruments and the SUSVIMO implant as the material of the septum and silicone encasing is soft and susceptible to damage.

Important Device Handling Information

- Use caution when performing ophthalmic procedures (e.g., B-scan ophthalmic ultrasound, scleral depression, or gonioscopy) that may cause deflection or movement of the implant and subsequent injury.

Ocular Implant Initial Fill Procedure

- Minimize air bubbles within the implant reservoir as they may cause slower drug release. If an air bubble is present, it must be no larger than 1/3 of the widest diameter of the implant. If excess air is observed after initial fill, **do not** use the implant.

Ocular Implant Insertion Procedure

- Perpendicular entry of the implant is important to avoid contact between the implant and intraocular structures such as the lens, as contact between the implant and the intraocular structures may cause adverse reactions such as traumatic cataract.
- Avoid excessive force on the globe by first ensuring that the tip of the implant has passed through the sclero-pars plana incision before slowly pushing the implant into place.

Ocular Implant Removal Procedure

- **Do not** grasp the implant by the short axis of the implant flange. Remove the implant in a gentle manner. Perpendicular exit of the implant is important to avoid contact between the implant and intraocular structures such as the lens.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Advise patients on the following after the implant insertion procedure:

Positioning:

- Keep head above shoulder level for the rest of the day.
- Sleep with head on 3 or more pillows during the day and the night after surgery.

How to care for the treated eye after the procedure:

- Do not remove the eye shield until they are instructed to do so by their healthcare provider. At bedtime, continue to wear the eye shield for at least 7 nights following the implant surgery.
- Administer all post-operative eye medications as directed by their healthcare provider.
- Do not push on the eye, rub the eye, or touch the area of the eye where the implant is located (underneath the eyelid in the upper and outer part of the eye) for 30 days following the implant insertion.
- Do not participate in strenuous activities until 1-month after the implant insertion or after discussion with their healthcare provider.

Magnetic Resonance (MR) Conditional information:

- The SUSVIMO implant is MR conditional. Inform their healthcare provider that they have SUSVIMO implanted in their eye and show their healthcare provider the SUSVIMO implant card should they require Magnetic resonance imaging (MRI).

Advise patients on the following after the Refill-Exchange procedure:

- Refrain from pushing on the treated eye, rubbing the eye, or touching the eye in the area of the implant (located underneath the eyelid in the upper and outer part of your eye) for 7 days following the refill-exchange procedure.
- Administer eye drops as directed by their healthcare provider.

Advise patients on the following after the implant removal procedure (if it is deemed medically necessary):

- Keep your head above shoulder level for the rest of the day.
- Sleep with your head on 3 or more pillows if lying down during the day and night after the implant removal.
- Wear an eye shield for at least 7 nights following the implant removal.
- Do not participate in strenuous activities until 14 days following the implant removal.
- Administer all post-operative anti-inflammatory and antimicrobial drops, as directed by your healthcare provider.

Advise patients on the following throughout SUSVIMO treatment:

- Do not drive or use machinery until the eye shield can be removed and visual function has recovered sufficiently [*see Adverse Reactions (6.1)*].
- The SUSVIMO implant and/or implant related procedures have been associated with conjunctival reactions (bleb, erosion, retraction), vitreous hemorrhage, endophthalmitis, rhegmatogenous retinal detachment, the dislocation of the implant, septum dislodgement, and a temporary decrease in vision.

- While the implant is in the eye, avoid rubbing the eye or touching the area as much as possible. However, if necessary to do so, make sure hands are cleaned prior to touching the eye.
- Seek immediate care from an ophthalmologist if there are sudden changes in their vision (an increase in moving spots, the appearance of “spider webs”, flashing lights, or a loss in vision), increasing eye pain, progressive vision loss, sensitivity to light, redness in the white of the eye, a sudden sensation that something is in their eye, or eye discharge or watering [*see Warnings and Precautions (5)*].

SUSVIMO® [ranibizumab injection]

Manufactured by:

Genentech, Inc.

A Member of the Roche Group

1 DNA Way

South San Francisco, CA 94080-4990

U.S. License No.: 1048

SUSVIMO is a registered trademark of
Genentech, Inc.

©2025 Genentech, Inc.

MEDICATION GUIDE
SUSVIMO® (suss-VIH-moh)
(ranibizumab injection)

for intravitreal use via SUSVIMO ocular implant

What is the most important information I should know about SUSVIMO?

SUSVIMO (ranibizumab injection) is delivered into the eye using the SUSVIMO implant. The SUSVIMO implant and the procedures to insert, fill, refill and remove the eye (ocular) implant can cause serious side effects including:

- **an eye infection (endophthalmitis).** Endophthalmitis is an infection of the eyeball that can cause permanent damage to your eye including blindness. **Call your healthcare provider right away if you have increasing eye pain, vision loss, sensitivity to light, or redness in the white of the eye.** Endophthalmitis requires urgent (same day) medical or surgical treatment.
- **a missing layer on top of the white part of the eye (conjunctival erosion).** Conjunctival erosion is an area that becomes missing (defect) in the layer (conjunctiva) that covers the white part of the eye which may result in exposure of the implant. **Call your healthcare provider right away if you have a sudden feeling that something is in your eye, if you have eye discharge, or watering of the eye.** Conjunctival erosion may require surgical treatment.
- **an opening of the layer that covers the white part of the eye (conjunctival retraction).** Conjunctival retraction is an opening or gaping in the layer (conjunctiva) that covers the white part of the eye which may cause the implant to be exposed. **Call your healthcare provider right away if you have a sudden feeling that something is in your eye, if you have eye discharge, or watering of the eye.** Conjunctival retraction may require surgical treatment.

See “**What are the possible side effects of SUSVIMO?**” for other serious side effects that may happen while in treatment with SUSVIMO.

To help prevent or keep these side effects from becoming more serious follow all post-procedure instructions your healthcare provider gives you. See “How will I receive SUSVIMO?”.

What is SUSVIMO?

SUSVIMO (ranibizumab injection) is a prescription medicine used to treat adults with:

- Neovascular (wet) Age-related Macular Degeneration (AMD) who have responded to at least two injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor in the gel-like part of the eye (intravitreal).
- Diabetic Macular Edema (DME) who have responded to at least two injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor in the gel-like part of the eye (intravitreal).
- Diabetic Retinopathy (DR) who have responded to at least two injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor in the gel-like part of the eye (intravitreal).

It is not known if SUSVIMO is safe and effective in children.

Do not receive SUSVIMO if you:

- have an infection in or around your eye.
- have active swelling around your eye that may include pain and redness.
- are allergic to ranibizumab or any of the ingredients in SUSVIMO. See the end of this Medication Guide for a complete list of ingredients in SUSVIMO.

Talk to your healthcare provider before receiving this SUSVIMO if you have any of these conditions.

Before receiving SUSVIMO, tell your healthcare provider about all of your medical conditions, including if you:

- are currently taking or have recently taken medicines that lower the chance of blood clots forming in the body such as warfarin, low or regular doses of aspirin, or nonsteroidal anti-inflammatory drugs (NSAID).
- are pregnant or plan to become pregnant. It is not known if SUSVIMO will harm your unborn baby. You should use birth control during your treatment with SUSVIMO and for 12 months after your last dose of SUSVIMO.

- are breastfeeding or plan to breastfeed. It is not known if SUSVIMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive SUSVIMO.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive SUSVIMO?

- SUSVIMO is implanted through the white part of the eye (sclera) by your healthcare provider.
- Your healthcare provider will refill your implant device every 6 months (about every 24 weeks) if you have AMD or DME or every 9 months (about every 36 weeks) if you have DR.
- If you miss a scheduled refill, call your healthcare provider as soon as possible to reschedule your refill. Your next refill should be given 6 months after your last refill if you have AMD or DME, or 9 months after your last refill if you have DR.

Your healthcare provider will give you instructions to follow after the implant insertion, the refill procedure, and the implant removal. The instructions may include:

After the Implant Insertion:

- **Positioning of your head**
 - Keep your head above shoulder level for the rest of the day.
 - Sleep with your head on 3 or more pillows during the day and night after your implant insertion.
- **How to care for your eye**
 - **Do not** remove the eye shield from your eye until you are told to by your healthcare provider. At bedtime, continue to wear an eye shield for **at least 7 nights** following the implant insertion.
 - Take all post-operative eye medicines as your healthcare provider tells you to.
 - **Do not** push on the eye, rub the eye, or touch the area of the eye where the implant is located (underneath the eyelid in the upper and outer part of your eye) for **30 days** following the implant insertion.
 - **Do not** participate in strenuous activities until 1 month after the implant insertion or after talking to your healthcare provider.
- **Magnetic Resonance Imaging (MRI) Implant Card**
 - Get your implant card from your healthcare provider after receiving the implant and keep the card in a safe place for future reference. The implant card contains important information about your SUSVIMO implant.
 - Show your current and future healthcare providers your implant card. This is important if you need to have an MRI. You may only receive an MRI under very specific conditions if you have the SUSVIMO implant. Your healthcare provider will review the information on the implant card and will let you know if you should receive an MRI.

After the Refill Procedure:

- **Do not** push on the eye, rub the eye, or touch the area of the eye where the implant is located (underneath the eyelid in the upper and outer part of your eye) for **7 days** following the refill procedure.
- Take eye drops exactly as your healthcare provider tells you to take them.

After the Implant Removal:

- Keep your head above shoulder level for the rest of the day.
- Sleep with your head on 3 or more pillows if lying down during the day and night after implant removal.
- Wear an eye shield for **at least 7 nights** following the implant removal.
- Do not participate in strenuous activities until **14 days** following the implant removal.
- Give all post-operative drops, as told by your healthcare provider.

These are not all the instructions you may receive from your healthcare provider. Following all post-procedure instructions may help prevent serious side effects or keep side effects from becoming more serious. See **“What is the most important information I should know about SUSVIMO?”**.

What should I avoid while receiving SUSVIMO?

- **Do not** drive or use machinery until the eye shield can be removed and you can see.
- **Avoid** rubbing your eye or touching the area of your eye where the implant is located as much as possible while the implant is in place. If you have to rub or touch your eye, wash your hands first.

What are the possible side effects of SUSVIMO?

See “What is the most important information I should know about SUSVIMO?” on the first page.

In addition to those side effects listed on page one, the SUSVIMO implant and the procedures to insert, fill, refill and remove the eye (ocular) implant can cause other serious side effects including:

- **Tear and separation of layers of the retina (Rhegmatogenous retinal detachment):** Rhegmatogenous retinal detachment is a tear and separation of one of the layers of the retina in the back of the eye that senses light. Call your healthcare provider or go to the emergency room right away if you see flashing lights, see a curtain or veil covering part of your vision, have a change in your vision, or a loss of vision. Rhegmatogenous retinal detachment requires surgical treatment.
- **Implant movement (Implant dislocation):** Tell your healthcare provider right away if you notice that the implant has moved out of place. This movement may require surgical treatment to correct.
- **Implant damage:** Damage to the implant that prevents continued treatment (refills) with SUSVIMO. If the implant is not able to be properly refilled, your wet AMD may be inadequately treated and your physician may remove the implant and/or change your treatment.
- **Bleeding (Vitreous hemorrhage):** Vitreous hemorrhage is bleeding within the gel-like substance (vitreous) inside of your eye. Call your healthcare provider right away if you have an increase in moving spots or what looks like spider webs in your vision as you may need an additional eye surgery.
- **Bump on top of the white layer of the eye (Conjunctival bleb):** Conjunctival bleb is a small bulge in the layer (conjunctiva) that covers the white part of the eye where the implant is inserted. This may be due to leakage of fluid from the inside of the eye. Call your healthcare provider right away if you have a sudden feeling that something is in your eye (foreign body sensation), see a bulge over the white part of your eye, if you have eye discharge, or watering in the eye. You may need medical or surgical treatment.
- **Temporary decrease in vision after the SUSVIMO procedure.**

The most common side effects of SUSVIMO include:

- blood on the white of the eye
- redness in the white of the eye
- eye pain
- sensitivity to light

These are not all the possible side effects of SUSVIMO.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

You may also report side effects to Genentech at 1-888-835-2555.

General information about the safe and effective use of SUSVIMO.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about SUSVIMO that is written for health professionals.

What are the ingredients in SUSVIMO (ranibizumab injection)?

Active ingredient: ranibizumab

Inactive ingredients: histidine HCl, polysorbate 20, sucrose.

Manufactured by: **Genentech, Inc.**, A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990
U.S. License No.: 1048

This Medication Guide has been approved by the U.S. Food and Drug Administration

Revised: 5/2025